Adding pembrolizumab to partial breast radiation for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This study tests whether giving the immunotherapy drug pembrolizumab (an immune-boosting treatment) alongside partial breast radiation can help people with early-stage triple-negative breast cancer whose tumors are 'cold' (less responsive to the immune system). The goal is to see if this combination can make the cancer more likely to shrink before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 20 years old and have been diagnosed with triple-negative breast cancer (a type that does not have estrogen, progesterone, or HER2 receptors).
- Your cancer must be at an early stage (stage IIA or higher but not spread to distant organs) and your tumor must be considered 'immune-cold' (low levels of immune cells and a low PD-L1 score below 10).
- You must not have had breast cancer before, and you must not have had chemotherapy or radiation in the past.
- You must be scheduled to receive radiation to only part of the breast (not the whole breast).
- You must be in generally good health (able to do daily activities, with minor limitations at most) and willing to sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of radiation plus an immunotherapy drug (pembrolizumab) to help your immune system fight metastatic triple-negative breast cancer after a prior immunotherapy has stopped working. The goal is to see if adding radiation can boost your body's response to treatment.
This trial tests a new way to treat triple-negative breast cancer before surgery by combining radiation therapy with an immunotherapy drug and chemotherapy. The goal is to see if this combination can shrink the tumor more effectively and improve outcomes.
This trial studies whether adding pembrolizumab (an immune “unlocking” drug) to radiation and another treatment that targets certain immune cells can improve outcomes for women with high-risk, early-stage triple negative breast cancer. You may be considered if your cancer has signs that it may respond less to immunotherapy on its own.
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy after surgery can improve outcomes for people with early-stage triple-negative breast cancer. The treatment you receive depends on the level of immune cells (TILs) found in your tumor.
This study tests whether adding the drugs pembrolizumab and olaparib (or similar “radiosensitizers”) to radiation can improve outcomes for women with advanced breast cancer that is triple-negative or ER-positive/Her2-negative. It’s designed for cancers that have spread or come back and where radiation is being considered to control disease.
This study tests a combination of radiation therapy and immunotherapy for people with advanced triple-negative breast cancer who haven't had chemotherapy for their advanced disease. It aims to see if adding radiation to standard chemotherapy can help shrink tumors and improve outcomes.
Hear when a new Triple-Negative Breast Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.